Login to Your Account



Clinic Roundup


Tuesday, February 14, 2012
• Diffusion Pharmaceuticals LLC, of Charlottesville, Va., said it started enrollment in a Phase I/II trial to test its lead drug, trans sodium crocetinate (TSC), as a first-line treatment in newly diagnosed patients with glioblastoma. The study is expected to enroll up to 68 patients. Clinical endpoints are overall survival at two years and progression-free survival at six months.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription